Financing HIV service provision in England: Estimated impact of the cost of antiretroviral combination therapy

International Journal of STD and AIDS

Volumn 9, Issue 9, 1998, Pages 512-517

  Beck, E J ^a   Tolley, K ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antiretroviral therapy; Cost estimates; English HIV service provision

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; FINANCIAL MANAGEMENT; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL SERVICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM;

ANTI-HIV AGENTS; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; ENGLAND; HEALTH SERVICES; HIV INFECTIONS; HUMANS;

EID: 0031669554     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462981922746     Document Type: Article

References (37)

1. Hammer SM. Advances in anti-retroviral therapy and viral load monitoring. AIDS 1996;10(suppl 3):S1-S11
2. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts between 200 and 500 per cubic millimeter. N Engl J Med 1996;335:1081-90
3. Saravolatz LD, Winslow DI, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1099-106
4. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91
5. Williams IG. Use of protease inhibitors. J HIV Comb Therapy 1996;1:4-7
6. Vella S, Florida M. Strategies for combination therapy. J HIV Comb Therapy 1996;1:8-10
7. Curtis H. Funding implications of combination therapy. J HIV Comb Therapy 1997;2:27-8
8. Forte P, Bowen T. HIV/AIDS Care and Treatment Costs: Forward Planning, London, UK: AIDS Awareness Trust, 1996
9. Department of Health Press Release. £23 Million Boost for Next Year's HIV/AIDS Treatment Budget, Whitehall, London: Richmond House, 27 October 1997
10. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. JAMA 1996;276:146-54
11. Gazzard B, Moyle CJ, Weber J, et al. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92
12. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997;277:1962-9
13. Beck EJ, Kennelly J, McKevitt C, et al. Changing use of hospital services and costs at a London AIDS referral centre 1983-1989. AIDS 1994;8:367-77
14. Kennelly JM, Tolley KH, Ghani ACH, Sabin CA, Maynard AK, Lee CA. Hospital costs of treating haemophilic patients infected with HIV. AIDS 1995;9:787-93
15. Nageswaran A, Kinghorn G, Shen R, Priesley C, Kyi T. Hospital service utilization by HIV/AIDS patients with their management cost in a provincial genitourinary medicine department Int J STD AIDS 1995;6:336-44
16. Beck EJ, Mandalia S, Power A, for the NPMS Steering Group. Service Activity by Stage of HIV Infection in NPMS Pilot Sites: January-June 1996. Coordinating and Analytic Centre, Department of Epidemiology and Public Health, Imperial College School of Medicine at St Mary's, London, UK, 1997
17. Beck EJ, Power A, Mandalia S, for the NPMS Steering Group. Service Activity by Stage of HIV Infection in NPMS Pilot Sites: July-December 1996. Coordinating and Analytic Centre, Department of Epidemiology and Public Health, Imperial College School of Medicine at St Mary's, London, UK, 1997
18. Beck EJ, Whitaker L, Kennelly J, et al. Changing presentation and survival, service utilization and costs for AIDS patients: insights from a London referral centre. AIDS 1994;8:379-84
19. Petrou S, Dooley M, Whitaker L, et al. Community services for people with HIV infection in London: a prospective study of cost and utilization patterns. Health Trends 1995;27:62-8
20. NHS Executive. Hospital and Community Health Services Revenue (Pay and Prices) Inflation Index. Leeds: NHS Executive Finance and Performance Department A, 1997
21. PHLS AIDS Centre. AIDS Surveillance and HIV Death Clinical Report Form. London, UK: PHLS Communicable Disease Surveillance Centre, 1993
22. Finkler SA. The distinction between cost and charges. Ann Intern Med 1982;96:102-9
23. Beck EJ, Mandalia S, Griffith R, et al. The Hospital and Community Services Study of Families with HIV Infection: Initial Analyses of Hospital Service Provision and Costs for HIV-infected Children St Mary's Hospital, 1986-1994. Department of Epidemiology and Public Health, Imperial College School of Medicine at St Mary's, London, UK, 1997
24. Beck EJ. The National Prospective Monitoring System - Another Successful English Export Product? NPMS Steering Group Meeting, Imperial College School of Medicine at St Mary's, London, UK, 5 December 1997
25. Anonymous. Glaxo Wellcome's quadruple HIV therapy. SCRIP, No 2278, p 22, 1997
26. Direction des Hospitaux, Mission SIDA. DM12: An Information System Built around the Patient. INSERM-SC4, Ministère de la Santé et de l'action Humanitaire, Paris, France, 1993
27. Beck EJ. Counting the cost of HIV service provision in England: where do we go from here? J HIV Comb Therapy 1997;2:29-32
28. Molesworth A. Results from the 1995 survey of prevalent clinically diagnosed HIV infection in England, Wales and Northern Ireland. CDR 1997;7:R77-82
29. Anonymous. AIDS and HIV infection in the United Kingdom: monthly report. CDR 1997;7:389-92
30. Perelson AS, Essunger P, Cao YZ, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997;387:188-91
31. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viraemia. Science 1997;278:1291-5
32. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300
33. Brown R, Simpson KN, Nabulsi A. Cost and consequences of adding ritonavir to current antiretroviral therapy for advanced HIV patients in the United Kingdom and in the USA (Abstract We.B.3126). XIth International Conference on AIDS, Vancouver, Canada, 1996
34. Simpson K, Revicki D, Nabulsi A, Sarocco P. Adding ritonavir to current antiretroviral therapy for advanced HIV patients in the US: comparison of costs of care predicted by modelling and actual costs from trial setting (Abstract Th.B.4112). XIth International Conference on AIDS, Vancouver, Canada, 1996
35. Beck EJ, Kupek EJ, Wadsworth J, Miller DL, Pinching AJ, Harris JRW. The use and cost of hospital services by patients with different AIDS defining conditions treated at a national London AIDS referral centre. J Public Health Med 1996;18:457-64
36. Dijkgraaf MGW, Luijben AHP, Jager JC, Schrijvers AJP, Borleffs JCC. Inpatient care for symptomatic HIV-infected persons: a longitudinal study of hospitalizations, inpatient drug use and related costs. AIDS Care 1995;7:321-36
37. Postma MJ, Tolley K, Leidl RM, et al. Hospital care for persons with AIDS in the European Union: assessment of current and future impact controlled for severity-stages. Health Policy 1997;41:157-76